Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole

ClinicalTrials.gov ID: NCT00314860

Public ClinicalTrials.gov record NCT00314860. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 6:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)

Study identification

NCT ID
NCT00314860
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
568 participants

Conditions and interventions

Interventions

  • ropinirole Extended Release (XR) Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 79 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2006
Primary completion
Nov 30, 2006
Completion
Nov 30, 2006
Last update posted
Oct 17, 2016

2006

United States locations

U.S. sites
28
U.S. states
16
U.S. cities
28
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35209
GSK Investigational Site Mesa Arizona 85210
GSK Investigational Site Phoenix Arizona 85050
GSK Investigational Site Sun City Arizona 85351
GSK Investigational Site Anaheim California 92801
GSK Investigational Site Burlingame California 94010
GSK Investigational Site Long Beach California 90806
GSK Investigational Site Newport Beach California 92660
GSK Investigational Site Pasadena California 91106
GSK Investigational Site Redondo Beach California 90277
GSK Investigational Site Santa Monica California 90404
GSK Investigational Site Stanford California 94305-5548
GSK Investigational Site Winnetka California 91306
GSK Investigational Site Boca Raton Florida 33486
GSK Investigational Site Coeur d'Alene Idaho 83814
GSK Investigational Site Springfield Massachusetts 01104
GSK Investigational Site West Yarmouth Massachusetts 02673
GSK Investigational Site Worcester Massachusetts 01655
GSK Investigational Site Kalamazoo Michigan 49048
GSK Investigational Site Saint Paul Minnesota 55101
GSK Investigational Site St Louis Missouri 63128
GSK Investigational Site Las Vegas Nevada 89119
GSK Investigational Site Albany New York 12205
GSK Investigational Site Tabor City North Carolina 28463
GSK Investigational Site Fargo North Dakota 58104
GSK Investigational Site Oklahoma City Oklahoma 73104
GSK Investigational Site Warwick Rhode Island 02886
GSK Investigational Site Burlington Vermont 05401

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 63 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00314860, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 17, 2016 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00314860 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →